

REMARKS**AMENDMENTS TO THE SPECIFICATION**

The Example section beginning on page 371, line 5 and continuing to page 506 of the substitute specification, submitted with Applicants January 5, 2005 Reply, was amended to correct typographical errors in the numbering of the Examples. Specifically, the numbering of all of the Examples residing subsequent to Example 9 was corrected to be in correct numerical order beginning with changing "Example 6" to "Example 10" and continuing to the end of the substitute specification. No new matter has been added.

STATUS OF THE CLAIMS:

Claims 1-25, 31 to 37, and 48 to 56 are cancelled.

Claim 68 was amended.

Claims 26 to 30, 38 to 47, and 57 to 69 are pending.

Claim 68 was amended to ensure the amino acid substitutions encompassed by Claim 58 are represented in this claim, as well as to ensure Claim 68 is not directed to the same subject matter as Claim 67. Specifically, the phrase "at amino acid residue 6," was deleted; the "and " term was deleted after the first "at amino acid residue 193" phrase; the phrase "and at amino acid residue 302," was appended after the first "at amino acid residue 284," phrase; the "is isoleucine" phrase after the "wherein the substitute amino acid at amino acid residue 5" phrase was deleted, and substituted with the phrase "represents an amino acid deletion at this position"; the "the substitute amino acid at amino acid residue 6 is valine," phrase was deleted; the "and" term was deleted after the "the substitute amino acid at amino acid residue 193 is asparagine," phrase; and the "and the substitute amino acid at amino acid residue 302 is alanine," phrase was added after the "the substitute amino acid at amino residue 284 is serine," phrase. Support for these amendments may be found in Claim 58. Applicants reserve the right to prosecute Claim 68 as originally presented in related applications. Applicants right to equivalents of Claim 68 is reserved. No new matter has been added.


CASE D0072 NP

If any small matter should remain outstanding after the Patent Examiner has had an opportunity to review the above Remarks, the Patent Examiner is respectfully requested to telephone the undersigned attorney in order to resolve these matters.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-3575


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: May 31, 2005